NanoGroup S.A. announced today, December 17, 2025, the closing of a 7.5 million PLN investment in Auxilius Pharma S.A. as part of a funding round totaling 15 million PLN. The capital was deployed through the subscription of Series D preferred shares by the ffVC fund, acting in concert with NanoGroup. This investment is a key component of the company’s long-term strategy to build a robust and diversified biotechnology group.

Use of proceeds

The funds will be allocated to conduct a Phase 1b clinical trial for Auxilius Pharma’s lead project, AUX-001, which is being developed for the treatment of chronic stable angina. The project leverages a well-established mechanism of action and a proven safety profile, while its innovation lies in the use of a modified-release formulation of the active ingredient.

Auxilius Pharma S.A.

The biotechnology company develops projects based on the Value Added Medicines (VAM) model, utilizing proven active substances in enhanced pharmaceutical forms. The company’s strategic focus is the US market; it is currently collaborating with the FDA and plans to submit a registration application in 2028, while simultaneously conducting negotiations for potential partnership agreements. Projects are executed via the FDA 505(b)(2) regulatory pathway, which accelerates development timelines, reduces costs, and mitigates clinical risk.

Strategy

NanoGroup’s investment in Auxilius Pharma S.A. aligns with the strategy of NanoGroup S.A., which aims to build a strong, diversified biotechnology group and generate stable, recurring revenue. Participation in projects with clearly defined market potential will allow NanoGroup S.A. to not only diversify its operations but also build long-term shareholder value

Additional Information: ffVC ASI II, acting in concert with NanoGroup S.A., has contributed PLN 7.5 million, while a further PLN 7.5 million will be provided by NCBR Investment Fund ASI S.A. as part of a co-investment.